Patents by Inventor Rodolfo Cadilla

Rodolfo Cadilla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THIAZOLE DERIVATIVES FOR TREATING PPAR RELATED DISORDERS
    Publication number: 20060276519
    Abstract: The present invention provides combinations of compounds of formula (I) and other therapeutic agents for the treatment of PPAR related diseases.
    Type: Application
    Filed: August 17, 2006
    Publication date: December 7, 2006
    Inventors: Rodolfo Cadilla, Romain Gosmini, Millard Lambert, Michael Sierra
  • Thiazole derivatives for treating PPAR related disorders
    Patent number: 7105551
    Abstract: The present invention provides compounds of formula (I).
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: September 12, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Rodolfo Cadilla, Romain Luc Marie Gosmini, Millard Hurst Lambert, III, Michael Lawrence Sierra
  • Chemical compounds
    Publication number: 20060148893
    Abstract: This invention relates to non-steroidal compounds that are or are believed to be modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.
    Type: Application
    Filed: June 9, 2004
    Publication date: July 6, 2006
    Inventors: Jean-Baptiste Blanc, Rodolfo Cadilla, David Cowan, Istvan Kaldor, Andrew Larkin, Eugene Stewart, Ryan Trump, Philip Turnbull
  • Chemical compounds
    Publication number: 20060142387
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.
    Type: Application
    Filed: June 9, 2004
    Publication date: June 29, 2006
    Inventors: Rodolfo Cadilla, Andrew Larkin, Eugene Stewart, Ryan Trump, Philip Turnbull
  • Hppars activators
    Publication number: 20050137212
    Abstract: Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseases or conditions associated with one or more of human PPAR alpha, gamma, or delta (“hPPARs”) comprising administration of a therapeutically effective amount of a compound of formula (1), are disclosed.
    Type: Application
    Filed: February 25, 2003
    Publication date: June 23, 2005
    Inventors: Rodolfo Cadilla, Brad Henke, Millard Lambert III, Guangcheng Liu, Jennifer Smith
  • Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
    Publication number: 20040072838
    Abstract: The present invention provides a compound of formula (1) wherein R1-R5, R25, R26, Y and X2 are defined as in claim 1. The compounds activate human peroxisome proliferator activated receptors (hPPARs) and arc useful for the treatment of associated disorders such as cardiovascular disease and hypercholesteremia.
    Type: Application
    Filed: October 31, 2003
    Publication date: April 15, 2004
    Inventors: Pierette Banker, Rodolfo Cadilla, Millard Hurst Lambert lll, Stephen William Rafferty, Daniel David Sternbach, Marcos Luis Sznaidman
  • Thiazole derivatives for treating ppar related disorders
    Publication number: 20040063964
    Abstract: The present invention provides compounds of formula (I). These compounds are used for the treatment of PPAR related diseases.
    Type: Application
    Filed: October 20, 2003
    Publication date: April 1, 2004
    Inventors: Rodolfo Cadilla, Romain Luc Marie Gosmini, Millard Hurst III Lambert, Michael Lawrence Sierra
  • Oxazole derivatives as antagonists of alpha 1C andrenergic receptors
    Patent number: 6090825
    Abstract: Oxazole compounds having formula (I) wherein R.sup.1 and R.sup.3 are selected from the group consisting of hydrogen, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkoxyC.sub.1-6 alkyl, phenyl or phenyl mono- or disubstituted with C.sub.1-6 alkyl, halogen, hydroxy, C.sub.1-6 alkoxy, aminosulfonyl, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkylsulfonylaminoC.sub.1-6 alkyl or carbamylC.sub.1-6 alkylaminosulfonyl; R.sup.2 is selected from hydrogen, C.sub.1-6 alkyl, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkoxyC.sub.1-6 alkyl or (fluorinated C.sub.1-6 alkyl)oxyC.sub.1-6 alkyl; W is a C.sub.1-6 alkylene chain or nitrogen; m is independently the integer 0 or 1; X is CH or nitrogen, provided that when W is nitrogen then X is CH; q is independently an integer selected from the group consisting of 1, 2, 3 or 4; or a pharmaceutically acceptable acid-addition or base-addition salt thereof, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: June 3, 1997
    Date of Patent: July 18, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: Robert Carl Andrews, Peter Jonathan Brown, Rodolfo Cadilla, David Harold Drewry, Michael Joseph Luzzio, Brian Edward Marron, Stewart Alwyn Noble